SCHEMBL15919378

SCHEMBL15919378

CC(C)(C)OC(=O)NNC(=O)c1cc(-c2ccc(C#C[Si](C)(C)C)c(F)c2)nc2ccncc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACB O00763 6/20 0.40
ACACA Q13085 5/20 0.40
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
GAA P10253 3/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP17A1 P05093 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919484 0.90 ACACB (0.39) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919373 0.89 ACACB (0.42) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919517 0.88 ACACB (0.44) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919376 0.84 ACACB (0.43) ACACBACACAMEN1KMT2AGAA
SCHEMBL15905078 0.81 MEN1 (0.51) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919491 0.81 KDM4E (0.41) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919508 0.80 ACACB (0.48) ACACBACACAMEN1KMT2AGAA
SCHEMBL15904908 0.80 ACACB (0.46) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919510 0.78 ACACB (0.50) ACACBACACAMEN1KMT2AGAA
SCHEMBL15919379 0.78 ACACB (0.36) ACACBACACAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ACACB 1141/4885ACACA 1262/4885MEN1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.